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Currently, the development and the implementation of the new biotechnological wound coverings (skin 
equivalents) designed for temporal or permanent replacement of damaged or destroyed areas of human 
skin remains extremely actual relevant in clinical practice. Skin equivalents or equivalents of individual 
skin layers which include alive cells of different types take a special place among the artifi cial wound 
coverings. They mostly contain two basic types of cells – fi broblasts and keratinocytes (together or sepa-
rately). Such bioconstructions are usually served as temporary coverings, which supply the damaged skin 
by biologically active substances and stimulate the regeneration of the patient's own tissues. In this re-
view we consider as commercially available wound coverings and those which are still studied in the 
laboratories. Until now ideal substitutes of natural skin have not yet created, so the efforts of many re-
searchers are focusing on the solution of this problem.
K e y w o r d s: artifi cial skin, skin equivalents or substitutes, wound dermal coverages, tissue engineer-
ing, cell, wound.
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Introduction
Autodermoplastics is traditionally used to cover vast 
wounds. However, this method does not allow cov-
ering the whole surface of the wound even with mesh 
autodermotransplantat, if the total area of the wound 
exceeds 30–40 % of the body area. One of the ways 
to solve this problem is the application of biotechno-
logical wound coverages, which may be divided into 
two kinds: non-cell ones and those, containing living 
cells of different types and origin. There are current-
ly no ideal bioconstructions, which would meet all 
the criteria, thus the research is still under way.
Let us consider the requirements to the ideal bio-
logical skin equivalent:
– no antigenicity; skin compatibility,
– no local or systemic toxicity,
– no permeability for exogenous microorganisms,
– inhibition of the activity of microorganisms in 
the wound,
– moisture permeability, similar to that of normal 
skin,
– suffi cient adhesion to the wound surface,
– compliance with the surface irregularities,
– elasticity, not disturbing the mobility of subicu-
lums,
– resistance to linear and shifting deformations,
– longitudinal strength,
– biodegradation ability,
– extensive lifetime and simplicity of storing,
– low cost,
– usability for medical staff,
– acceptability and minimal discomfort for a pa-
tient,
– semitransparency to have the possibility of ob-
serving the process of wound healing,
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– shortened time of wound healing [1].
Experimental data prove the relevance of the con-
tact of wound surface and different types of cells, 
which may be a part of artifi cial skin substitutes. At 
present there are two main types of cells, which are 
the components of clinically available bioconstruc-
tions, – keratinocytes and fi broblasts (together or 
separately). The processes of proliferation and dif-
ferentiation of keratinocytes are known to have bet-
ter performance in the presence of fi broblasts; in 
turn, the functional state of fi broblasts depends on 
the effect of keratinocytes [2]. For instance, it was 
demonstrated that biologically active substances, 
discharged by fi broblasts, affect the proliferation and 
migration of skin melanocytes [3]. At the same time 
all the clinically applied skin equivalents do not con-
tain any nervous or immune cells, sweat glands and 
hair follicles, therefore, they are not capable of per-
forming all the skin functions. As a rule, these bio-
constructions act as temporary biologically active 
wound coverages, providing the damaged tissues 
with the components of extracellular matrix, cyto ki-
nes and growth factors (vitronectin, tenastin, colla-
gen, glycosaminoglycans, interleukins 1, 6, 8, inter-
ferons α and β, PDGF, FGF-1, KGF-1, PDGF, VEGF 
(vascular endothelial growth factor), TGF-α) [4, 5]. 
Due to this fact there is the migration of the recipient 
organism cells into the wound area along with their 
proliferation, regeneration of the dermal layer and 
wound re-epithelization, the wound area is «condi-
tioned» for the use of skin transplantats. It promotes 
shortening the period of wound healing and prevents 
the formation of adhesions and scars compared to 
the cell-free bioactive wound coverages [6].
The application of autologous cells to obtain skin 
equivalents prevents the possibility of immune re-
jection and the infection of a patient with foreign 
microorganisms, but it hinders obtaining of the prod-
uct at the required moment and increases the cost of 
its production. Taking these two problems into con-
sideration, the preference is given to the connective 
tissue cells, fi broblasts; this fact is confi rmed by the 
communications about temporary immunogenic tol-
erance of the recipient organism to the allogeneic fi -
broblasts and their survival and proliferation in the 
donor organism for up to two months without the 
symptoms of the immune rejection [7, 8]. At the sa-
me time the allogeneic keratinocytes are highly im-
munodominant, they are rejected by the organism 
and usually perish several weeks after the applica-
tion onto the wound [9]. This earlier death, compared 
to the allogeneic fi broblasts, is likely to be the conse-
quence of a high level of expression of human leuko-
cyte antigen (HLA).
I. Epidermal equivalents
With the possibility of cultivating human keratinoc-
ytes in vitro and multiple increase in their total num-
ber [10], they were applied in the wound treatment 
[11], which promoted the survival of some serious 
Table 1. The application of epidermal equivalents
Brand Producer, country Objects for application
Epicel Genzyme Biosurgery, Cambridge, MA, USA Massive burns [13]
EPIBASE Laboratoires Genevrier, Sophia-Antipolis, Nice, France Massive burns [13]
EpiDex Modex Therapeutiques, Lausanne, Switzerland Massive burns [13]
MySkin CellTran Ltd, Sheffi eld, UK Ulcers of lower extremities, superfi cial scalds; donor 
sites for skin transplantat [28, 29]
Laserskin
or Vivoderm
Fidia Advanced Biopolymers, Padua, Italy Preclinical animal tests [30, 31]
Moderate clinical trials [32]
Bioseed-S BioTissue Technologies GmbH, Freiburg, Germany Chronic venous ulcers of lower extremities [33, 34]
Full thickness wounds of animals [22]
CellSpray Clinical Cell Culture (C3), Perth, Australia Partial thickness wounds; donor sites for skin 
transplantats [13]
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patients [12]. The creation of epidermal equivalents 
involves the application of autologous keratinocytes, 
isolated from small (2–5 cm2) skin biopsy samples 
and proliferating in the culture with the formation of 
multilayer epithelial layers. These layers may be en-
zymatically separated from the surfaces of cultural 
vials and transferred to the supporting substrate, for 
instance, wax-bearing gauze or other carriers. This 
construction is applied to the wound taking into ac-
count basal-apical orientation of cells [13].
Using the modern methods of keratinocyte expan-
sion in vitro, it is possible during 3–4 weeks to ob-
tain from 3 cm2 of the tissue the epithelial autotrans-
plantats, large enough to cover the whole body sur-
face [14]. The drawbacks of such plate-like epithe-
lial autotransplantats are long-term cultivation, fra-
gility, complicated application of transplantats, and, 
mainly, unexpected clinical results in terms of differ-
ent degree of acceptability – 15 to 85 % [13, 15]. 
The enzymatic processing may change the struc-
ture of fi brils, responsible for the interaction of ke-
ratinocytes and the tissues of the recipient organism 
[16, 17]. Due to this fact there is weak adhesion of 
the transplantat to the wound and the formation of 
blisters in case of even insignifi cant shifts months 
after the transplantation [11]. The cultivation of ke-
ratinocytes on special delivery membranes, which 
will be later applied to the wound surface along with 
the cultivated cells, allows avoiding the requirement 
of using enzymes [16, 18] and promotes the prolif-
eration process, especially if natural, not synthetic, 
material is used. In particular, if fi brin is used as 
scaffold [18], the rate of transplantat formation in-
creases almost three-fold.
At present epidermal equivalents are almost ab-
sent in the burn centers of Ukraine. Common draw-
backs of these skin substitutes are the impossibility 
of their independent application in the therapy of full 
thickness wounds, only in the combination with der-
mal transplantats [19, 20] as well as their high cost. 
Well-known epidermal equivalents Epicel [12], 
EPIBASE [21] and EpiDex [22], the earliest among 
similar bioconstructs, are mere sheets of keratinoc-
ytes, cultivated for 15 days. In addition to the above-
mentioned drawbacks, they have short (24 hours) 
shelf life [23]. Another commercial product, MySkin 
[24], consists of a scaffolding silicon membrane, 
covered with subconfl uent layer of the cultivated ke-
ratinocytes. The keratinocytes of the product Laser-
skin (Vivoderm) [25] form a confl uent layer on the 
surface of the hyaluronic micromeshed membrane 
and are capable of migrating downwards, through 
the scaffold, to the wound bed.
Products Bioseed-S [26] and CellSpray [27] in-
volve the use of keratinocytes, composed of the sub-
confl uent layer, in their most active proliferation 
state. The keratinocytes of the product of Bioseed-S 
company are evenly distributed inside the fi brin gel 
of allogeneic origin. Product CellSpray is merely 
the suspension of keratinocytes. After the applica-
tion onto the wound surface the proliferation of ke-
ratinocytes continues up to the formation of the epi-
thelial skin layer [14, 26, 27].
II. Dermal equivalents
Only a few of current dermal skin substitutes con-
tain cells, since the production of large amounts of 
cell-free constructions is much easier and cheaper 
in large patches and it is much simpler to receive 
the license for their clinical application. It should 
be noted that dermal cellular coverages are almost 
unavailable for the application in burn centers of 
Ukraine.
As for well-known product TransCyte (previous 
name – Dermagraft-TC), the cultivated allogeneic 
fi broblasts are immobilized on the surface of the 
composite consisting of a silicon fi lm, a nylon net 
and dermal porcine collagen. This temporary dermal 
coverage for the wound bed has to be removed after 
7–14 days and replaced by the autotransplantat. The 
scaffold of Dermagraft [35] consisting of polygly-
colic acid, polylactic acid and extracellular matrix 
degrades on the wound surface via hydrolysis in 20–
30 days. The extracelular matrix is produced by the 
cellular component, presented by cultivated alloge-
neic fi broblasts.
The bioconstruction Hyalograft 3D [36, 37] is 
formed by the hyaluronic micromeshed membrane, 
which is the scaffold for cultivated autologous fi -
broblasts.
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III. Dermo-epidermal (composite)
skin substitutes
The dermo-epidermal equivalents contain cultivated 
fi broblasts and keratinocytes, located in different 
layers of the bioconstruction.
The bioengineered construction Apligraf (Apli graf 
Organogenesis Inc., USA) is currently the most suc-
cessful clinical dermo-epidermal equivalent [9]. The 
cells of allogeneic origin form a confl uent layer in the 
gel matrix of bovine type I collagen. The product is a 
temporary transplantat, resorbed on the wound surface, 
its drawback being short shelf life (up to 5 days).
The allogeneic fi broblasts of OrCell (OrCel Ortec 
International, Inc., USA) are immobilized inside the 
sponge-like gel of bovine type I collagen, one side of 
which has a formed confl uent layer of allogeneic ke-
ratinocytes. The product is resorbed on the wound 
surface 7–14 days after the application.
The scaffolding porous matrix of PolyActive [44, 
45] (PolyActive HC Implants BV, the Netherlands) 
consists of a soft component – poly(ethylene oxide) 
(PEO) – and a solid component – poly(butylene te re-
phthalate) (PBT); it contains autologous cultivated 
cells. Notably, this bioconstruction is mainly used 
for bone reconstruction rather than for skin repair.
The Product TissueTech Autograft System (Fidia 
Advanced Biopolymers, Italy) [46]) is not a «pure» 
two-layer skin substitute, but rather the combination 
of dermis equivalent Hyalograft 3D and epidermis 
equivalent Laserskin.
IV. The search for novel bioengineered
skin equivalents, containing cells
The elaboration of matrices using gelatin
Gelatin, a natural product, is formed due to partial 
denaturation and degradation of collagen fi brils and 
like collagen is the attractant for fi broblasts in the 
wound healing processes [49, 50]. Because of low 
cost and the possibility of in vivo degradation, gela-
tin is widely used as a coverage in wound treatment 
[51, 52, 53]. Other useful properties of gelatin are 
the absence of antigen activity, contrary to collagen 
[54], and strong hemostatic effect [54, 55]. As gela-
tin is water-soluble, the molecules of gelatin-con-
taining structures should be cross-linked for the ap-
plication in long-living bioconstructions.
Table 2. The application of dermal equivalents
Brand Producer, country Objects for application
TransCyte
(Dermagraft-TC)
Advanced BioHealing, Inc., New York, 
NY and La Jolla, CA, USA
Burn wounds of partial thickness; donor sites of skin transplantats 
[38, 39, 40].
Dermagraft Advanced BioHealing, Inc., New York, 
NY and La Jolla, CA, USA
Diabetic ulcers of lower extremities [41]. Venous ulcers [42]. Burn 
wounds.
Hyalograft 3D Fidia Advanced Biopolymers, Abano 
Terme, Italy
The stimulation of dermal-epidermal maturity [36, 37]. Ulcers of 
lower extremities (in combination with Laserskin) [43].
Table 3. The application of dermo-epidermal equivalents
Brand Producer, country Objects for application
Apligraf Organogenesis Inc., Canton, Massachusetts, 
CA, USA
Partial thickness burns [47, 48].
Diabetic ulcers on legs [9].
OrCel Ortec International, Inc., New York, NY, USA Burn wounds; donor sites for skin transplantats [6].
PolyActive HC Implants BV, Leiden, the Netherlands Partial thickness wounds; donor sites for skin transplantats 
[44, 45].
TissueTech 
Autograft System
Fidia Advanced Biopolymers, Abano Terme, 
Italy
Ulcers of lower extremities.
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S. B. Lee et al. [56] described that the scaffold for 
human fi broblasts and keratinocytes was the surface 
of a porous matrix, consisting of gelatin and (1-3),(1-
6)-β-glucan. The latter is the carbohydrate of the mi-
croorganism Schizophyllum commune, which dem-
onstrates the antibacterial, antiviral, anticoagulant 
and wound-healing activity [57].
Noteworthy is the work of H. M. Powell and S. 
T. Boy ce [58] who used a fi brous matrix, formed by 
the electrospinning method. The composition of the 
construction included human fi broblasts and kerati-
nocytes, forming confl uent cellular layers between 
the fi brils. It should be noted that electrospinning is 
the high voltage process of creating long fi brils 
with the diameter ranging from nanometers to frac-
tions of micrometer. Such e-spun fi brils are remark-
able for high poro sity and strong interrelation be-
tween the pores [59].
In contrast to the abovementioned works, Sh. 
Huang et al. [60] obtained so called gelatin micro-
spheres of dozens to hundreds of micrometers, and 
viewed gelatin as a potential depot for the biologi-
cally active substances. Then the surfaces of micro-
spheres were used to cultivate multipotent mesen-
chymal stromal cells (MMSC) of murine bone mar-
row, after which the microspheres were mixed with 
the solution of type I collagen. After gelatin jellying 
these bioconstructions were tested for treating burn 
wounds of mice with positive results.
Other authors, R. Quan et al. [61] used lyophiliza-
tion while creating the cellular scaffold of the follo-
wing composition – gelatin + chondroitin-6-sulfate + 
+ hyaluronic acid. The stem cells of hair follicles, ra-
rely used in similar research, served as a cellular com-
ponent. The potential of these bioengineered prod-
ucts in the therapy of skin damage of laboratory rats 
was demonstrated. 
R. V. Shevchenko et al. [62] used a bilayer cellular 
scaffold. The porous layer of gelatin contained human 
primary fi broblasts, and the silicon layer with smaller 
pores was cultivated with human keratinocytes. From 
the authors’ standpoint, the results of the application 
of this dermal substitute in treating porcine skin dam-
age allowed considering it as one of the biomedical 
constructions which will be used in future.
The elaboration of matrices using collagen
As shown by many authors, collagen is a good sub-
strate for adhesion and proliferation of the cultivated 
cells. For instance, in the work of J. George et al. 
[63] the collagen porous matrix was applied on the 
layer of proliferating fi broblasts, which entered the 
pores and prolonged the proliferation for 60 days. As 
a result, the formed structure was morphologically 
similar to the dermal skin layer.
Different groups of researchers, for instance, A. Kin-
ster et al. [64], S. H. Ahn et al. [65] also created po-
rous collagen matrices. In these constructions fi brob-
lasts were located inside the porous layer, whereas 
keratinocytes were on its surface, forming a well-de-
veloped multilayer epithelium [64] and even the ex-
ternal stratum corneum [65] similar to natural skin. A. 
El Ghalbzouri et al. [66] obtained the bioconstruction 
with a similar structure and cell distribution, but they 
created the matrix using human procollagen-I instead 
of commonly applied murine or bovine collagen.
In contrast to the abovementioned works, Kuikui 
Hu et al. [67] used as a scaffold the compressed col-
lagen gel, obtained from the polymerized collagen 
with incorporated murine fi broblasts under pressure 
the compressed gel lost water and shrank while dry-
ing out, its mechanical properties were improved 
and the concentration of cells was increased. The 
murine keratinocytes formed a multilayer analogue 
of epidermis while being cultivated on the gel sur-
face. The compression of collagen hydrogel, con-
taining fi broblasts, was also used by C. Helary et al. 
[68]. The hydrogel became more stable and provided 
more effective proliferation of inside cells under fa-
vorable storage conditions. 
The group of authors, H. M. Powell et al., used a 
sponge, made of collagen and chondroitin-6-sulfate, 
as a scaffold for human fi broblasts and keratinocytes 
[69]. In another work of the same group [70] a fi -
brous collagen matrix for cells was made by electro-
spinning. A similar fi brous scaffold for fi broblasts 
and keratinocytes was made by M. Kempf et al. [71] 
using bovine collagen-I.
The group of scientists from Great Britain and Tai-
wan [72, 73, 74] synthesized a copolymer fi lm using 
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the combination of collagen and poly-ε-caprolactone 
(PCL) in 1:20 ratio. The latter is a biocompatible 
polymer [75], capable of enzymatic biodegradation 
[76]. At cultivation, one side of the fi lm was covered 
with fi broblasts and other – with keratinocytes. J. 
Venugopal and S. Ramakrishna [77] obtained the co-
polymer nanofi brils using the combination of colla-
gen and poly-ε-caprolactone via the electrospinning. 
Human fi broblasts were cultivated on the spun ma-
trices. In [78] Ma et al. for the electrospinning of fi -
brils used collagen and polymer poly-(D,L)-lactic-
co-glycolic acid (PLGA), consisting of residues of 
lactic and glycolic acids at a ratio of 75:25, which is 
capable of biodegradation via hydrolysis. Human 
MMSC of bone marrow were used as a cellular com-
ponent. As shown by the experiments on rats, the 
product obtained promoted the collagen synthesis 
and epithelium maturation in the wound bed.
M. Ananta et al. [79] used the combination of col-
lagen with the same polymer; the latter was described 
as poly-(lactide-co-glycolide) (PLGA) and had com-
mercial name Vicryl. The collagen layer with fi brob-
lasts, evenly distributed within the volume, contained 
a PLGA net, which served as a frame to strengthen 
the construction. One of the surfaces of the collagen 
sheet carried keratinocytes. The cells were obtained 
using the skin of laboratory rabbits; further on the 
rabbits were used for the experiments, aimed at the 
study of the effi ciency of applying this skin equiva-
lent in burn therapy. The authors concluded that the 
bioconstructions obtained enhanced wound healing.
Noteworthy is the experimental work, in which P. 
Liu et al. [80] obtained MMSC out of bone marrow 
and cultivated them on the surface of the membrane, 
containing collagen and glycosaminoglycans. These 
bioconstructions were used in skin burn therapy. 
Yorkshire swines were used as laboratory animals to 
obtain MMSC and to simulate burns. The results 
were the improvement of wound vascularization, the 
stimulation of wound healing and the formation of 
epidermal skin layer.
In contrast to the abovementioned work, M. Keck 
et al. [81] cultivated human keratinocytes and preadi-
pocytes on the previously constructed bioconstruction 
Matriderm®, which was a sheet of bovine collagen, 
covered with dried hydrolysate of connective α-elastin. 
Keratinocytes formed a confl uent layer on the surface 
and preadipocytes penetrated into the samples.
Finally, R. K. Chan et al. [82] tried to create all 
three layers of skin coverages. The basis of the cel-
lular component was adipose-derived stem cells 
(ASCs). The matrices for cellular masses were for-
med out of collagen, polyethylene glycol and fi brin. 
The incubation of separate constructions with cells 
in cultural media of different composition was used 
to achieve the transformation of ASCs into epithelial 
and adipose cells. During the creation of a dermal 
equivalent the cells did not undergo directed differ-
entiation. The preclinical trials of the bioconstruc-
tions obtained are not described in the article, how-
ever, it can be understood («Further demonstration 
of this methodology in a preclinical model is under 
way») that to the moment of the article submission 
they have already been started.
The work of M. Itoh et al. [83] is noteworthy for 
the fact that they used human induced pluripotent 
stem cells (iPSC) as a source of cells. Previously 
these authors have informed about the possibility of 
artifi cial activation of iPSC differentiation into ke-
ratinocytes. In the mentioned work they developed a 
protocol of differentiating the same human iPSC into 
dermal fi broblasts. During the experiments they ma-
de samples of skin equivalents, containing the same 
cells, as those formed at the directed differentiation 
of iPSC. A collagen layer was applied on the surface 
of the polyethylene-terephthalate membrane, and af-
ter polymerization the fi broblasts and keratinocytes 
were cultivated consecutively, with the interval of 
5–7 days. The authors did not conduct any preclini-
cal trials of the bioconstructions obtained, but they 
informed that the histological structure was compat-
ible with that of the equivalents, obtained using a 
similar method but with the application of normal 
human fi broblasts and keratinocytes.
The elaboration of matrices using
chitin/chitosan and other materials
Chitin is a straight chain polysaccharide, whose mo-
no mer unit, N-acetylglucosamine, is a part of hyalu-
ronic acid, capable of stimulating dermis regenera-
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tion. Therefore chitin promotes the wound healing. 
Chitosan is a product of partial deacetylation of chitin 
and its separate monomer links. It should be noted 
that chitin and chitosan are biocompatible, i.e. they do 
not cause infl ammatory or allergic reactions after lo-
cal application or implantation into a human body 
[84], may be resorbed under the lysozyme action [85], 
and have bacteriostatic and fungistatic activity [86].
The example may be found in the work of G. M. 
Mykhailov et al. [87] who synthesized elastic chitin 
fi brils and wove a fi lm of them. This fi lm was later 
used to cultivate human fi broblasts, attached to the 
fi brils and fl attened against them. A. B. Hilmi et al. 
[88] also used only two components – chitosan and 
primary fi broblasts of human origin, but the chitosan 
scaffold was made in the form of porous sheets, with 
the cells located inside them.
Two groups of researchers [89, 90] created a po-
rous matrix using the mixture of collagen and chi-
tosan solutions. The latter increases matrix biostabil-
ity, which was demonstrated in the tests with colla-
genase [89] and lysozyme [90]. Human fi broblasts 
[90] or murine fi brosarcoma L929 cells [89] were 
used as a cellular component.
A noteworthy experimental work was conducted 
by I. N. Bolshakov et al. [91] who used as a cellular 
scaffold the collagen-chitosan complex, containing 
ascorbic, chondroitin-serine and hyaluronic acid, 
heparin and a medical preparation Adhelon (based 
on the bovine serum growth factor). They obtained 
fi lms or porous sheets, on the surface of which the 
fetal murine fi broblasts were cultivated. The experi-
ments with rats demonstrated that the application of 
these bioconstructions promotes complete restora-
tion of the epidermal-dermal complex to the state, 
corresponding to that of healthy skin.
A. V. Yeremeyev et al. [92] observed good prolif-
erative and metabolic activity of fetal murine fi brob-
lasts and MMSC of adipose murine tissue while cul-
tivating them on wound collagen-chitosan coverage 
Collakhit-bol (Patent of the Russian Federation N 
2252787, 27.05.2005; Patent of the Russian Fe de-
ration N 2254145, 20.06.2005). During cultivation 
the stromal cells started to differentiate into epithe-
lial ones. J. Mao et al. [93] experimented with the 
cellular scaffold, consisting of chitosan and gelatin 
layers. Human fi broblasts and keratinocytes were 
used as a cellular component. The latter were intro-
duced into the bioconstruction some time after the 
cultivation of fi broblasts on the matrix. Contrary to 
the abovementioned works, C. M. Han et al. [94] 
created a collagen-chitosan porous membrane. After 
a week-long cultivation its surface was covered with 
a fi brin layer, on which a layer of human keratinoc-
ytes was applied.
An original work was performed by Sh. Ikemoto 
et al. [95], where the authors succeeded in cultivat-
ing human keratinocytes on the membrane, consist-
ing of chitosan, conjugated with protein AG73. This 
is one of representatives of the family of laminins – 
over 30 large glycoproteins, located on the basal 
membrane. Among them, AG73 peptide is the most 
effi cient stimulator of cell migration, adhesion and 
stimulation of axon germination. The authors deem 
their product to be a good vehicle to deliver kerati-
nocytes to the wound bed.
Two groups of researchers [96, 97] used the elec-
trospinning method to obtain cation nanofi brils us-
ing two components: chitosan, carrying short oligo-
mer fragments of poly-ε-caprolactone (chitosan-graft-
poly-ε-caprolactone), and pure poly-ε-capro lac tone. 
The samples obtained demonstrated suffi ci ent prolif-
eration of murine fi brosarcoma L929 cells [96, 97], 
human osteosarcoma MG63 cells [97], fetal murine 
fi broblasts NIH3T3 [97].
The elaboration of matrices
using hyaluronic acid
Hyaluronic acid is a polymer, consisting of the resi-
dues of D-glucuronic acid and D-N-acetylglu co sa mi-
ne, successively connected by β-1,4- and β-1,3-gly co-
sidic linkage. Natural molecules of hyaluronic acid 
may contain up to 25.000 disaccharide links. This 
substance , being one of the main components of a 
extracellular matrix, is a part of many biological fl u-
ids, participates in the processes of adhesion, migra-
tion and proliferation of fi broblasts and keratinoc-
ytes as well as in fetal non-scar wound healing [98].
Let us consider the series of experimental works 
involving the application of hyaluronic acid. T. W. Wang 
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et al. [99] prepared a composite matrix via polym-
erization of the solution, containing gelatin, hyalu ro-
nic acid and chondroitin-6-sulfate in the concentra-
tions of 5 %, 0.2 % and 0.05 % respectively. H. Liu 
et al. [100, 101] synthesized the matrix using the so-
lution of gelatin, chitosan acetate and hyaluronic 
acid in the concentrations of 0.7 %, 0.4 % and 0.001 
% respectively. During the process of combined cul-
tivation on the composite biopolymers the obtained 
human fi broblasts and keratinocytes demonstrated 
high viability and proliferation ability. The works 
[100, 101] showed that after two weeks keratinocytes 
gradually self-organized into a layer-like structure, 
which in particular included the layer of cubic cells 
and the surface layer of compressed cells. H. M. Wang 
et al. [102] also created a three-component matrix, 
consisting of collagen, hyaluronic acid and gelatin, 
whereas the cellular component included three types 
of cells instead of two: keratinocytes, melanocytes 
and fi broblasts. The skin equivalent obtained promot-
ed wound healing in the in vivo experiments.
Noteworthy is the work, in which N. Scuderi et al. 
[103] described a clinical case of treating a surgical 
wound using the bioconstruction, based on the ma-
trix of polymerized hyaluronic acid. The fi broblasts, 
keratinocytes and melanocytes, obtained during skin 
biopsy prior to the surgery, were jointly cultivated 
on this matrix. J. Enrione et al. [104] studied me-
chanical and physical properties of the same matrix 
and checked its cytotoxicity using cultivated human 
fi broblasts.
In the following work Sh. Kondo et al. [105] pre-
pared composite porous matrices using hyaluronic 
acid, cross-linked collagen and epidermal growth 
factor (EGF). The latter considerably stimulated the 
fi broblasts proliferation on the matrix surface along 
with the formation of granular tissue in the wound, 
angiogenesis and epithelization of the wound in the 
experiments with rats.
The elaboration of matrices
using different synthetic polymers
The fi lm of the abovementioned poly-ε-caprolactone 
(PCL) was used in the work of K. W. Ng et al. [75] 
as a scaffold for human fi broblasts. Arun Richard 
Chandrasekaran et al. [106] used the electrospinning 
method to create fi brils, containing poly-L-lactic-
acid-co-poly-ε-caprolactone and gelatin. Human fi -
broblasts served as a cellular component of the bio-
construction.
In the works of two groups, K. A. Blackwood et 
al. [107], S. G. Kumbar et al. [108], the combination 
of solutions of lactic and glycolic acids was used to 
elaborate copolymer fi brils of the poly(lactide-co-
glycolide) composition using the electrospinning 
method. This polymer has been mentioned above, 
but the authors of these works did not combine it 
with other materials. The fi brils obtained were used 
to spin biodegradable scaffolds for human fi brob-
lasts and keratinocytes [107] or for human fi brob-
lasts only [108]. In [107] the most effi cient ratio of 
polylactic and polyglycolic acids was estimated to 
be 85:15 or 75:25.
Other materials, used to elaborate matrices
Complex matrices were made by A. L. Mazlyzam et 
al. [109]: for instance, they initiated the polymeriza-
tion of human fi brin in the suspension of human fi -
broblasts. The abovementioned gel layer, carrying 
keratinocytes, was formed in a similar way. A layer 
of silk was applied for stabilization during the trans-
portation and transplantation.
Human amniotic membrane was used as a cell scaf-
fold in two works. S. S. Kim et al. [110] immobilized 
rabbit mesenchymal stromal cells (MSC) on its sur-
face. In the work of Lujun Yang et al. [111] at fi rst the 
membrane surface was covered with fi broblasts after 
the removal of the epithelial layer. Five days later, 
when the fi broblasts penetrated the membrane stroma, 
the surface was seeded with keratinocytes.
The remarkable work was performed by C. 
Castagnoli et al. [112], in which the cell-free dermal 
layer of dead donor skin was used to create a skin 
equivalent. Then they cultivated keratinocytes on its 
surface for 21 days.
A work to be noted is the research of Chung Eun 
Yeum et al. [113] who cultivated MMSC, obtained 
from the bone marrow of laboratory mice, on the 
surface of small intestinal submucosa (SIS), one of 
the layers of intestinal walls, mechanically stable 
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and formed by porous connective tissue. It was dem-
onstrated that cells migrated from the surface of this 
scaffold into the wound bed, evolving growth fac-
tors. Here the number of cells, migrating to the 
wound surface, reached some maximal value (de-
pending on the wound size) and further on remained 
constant, even if the number of MMSC, brought to 
the wound bed in the composition of transplantats, 
was increased.
V. Our studies on the basis
of Human Genetics Department
of IMBG NAS of Ukraine.
Since 2001 we have conducted biotechnological re-
search in developing dermal skin equivalents, con-
taining living human cells. Human multipotent mes-
enchymal stromal cells (MMSC) of different origin 
were studied as a cellular component. Primary skin 
cells and the cells of 4BL line were used [114]. 
Currently MMSC, obtained from human placenta, 
became a new source of cells [115, 116]. The works 
in obtaining dermal skin equivalents using MMSC 
are being conducted in the collaboration with the 
Cell Therapy Institute, Kyiv, which has a license 
(AG 579626) for the elaboration and maintenance of 
low temperature bank of human cells and tissues.
Different materials of synthetic and natural origin 
are used as a scaffold. Previously there have been 
some experiments with hydrogel membranes, syn-
thesized in the F. D. Ovcharenko Institute of 
Biocolloid Chemistry NASU (Kyiv) using combined 
polymerization of acrylamide and acrylonitrile [117, 
118]. There have been joint clinical studies of differ-
ent dermal coverages on the limited number of pa-
tients with massive and deep burns in the collabora-
tion with the Center of Thermal Injuries and Plastic 
Surgery of the Kyiv City Hospital No. 2. The sam-
ples of hydrogels, based on the synthetic polyacryla-
mide matrix and natural collagen matrix with immo-
bilized MMSC, were applied on the wounds, previ-
ously cleansed from necrotic tissues. Twenty-four 
hours later the temporary dermal coverages were re-
moved with the subsequent autotransplantation of 
skin. In the control cases the autotransplantation of 
skin was conducted without previous application of 
hydrogel dermal coverages on wounds. It was dem-
onstrated that both synthetic and natural biomatrix/
cell constructions were non-toxic, solid, elastic, 
transparent or semitransparent, with good fi xation 
on the wound and partial adsorption of excessive tis-
sue exudate, and convenient in the application. The 
use of temporary skin substitutes made subsequent 
fi xation of meshed autotransplantats more reliable, 
accelerated their transfer to the vascular type of nu-
trition and increased the rate of epithelization of 
meshed spaces almost twice. The positive results of 
clinical trials allowed receiving two patents of 
Ukraine Patent of Ukraine (N 20134, 15.01.2007; 
Patent of Ukraine N 82583, 10.01.2008), the third 
patent is currently being considered.
Conclusion
At the current stage of biotechnology development 
the available epidermal, dermal and dermo-epider-
mal skin equivalents are not capable of replacing 
skin tissue completely. Usually they serve as a tem-
porary biologically active coverage, providing the 
damaged part of skin with cytokines, growth factors 
and other biologically active substances, which pro-
motes wound healing due to the stimulation of re-
generation of the patient’s own tissues. Therefore, 
the skin substitutes play a incomplete, yet relevant 
role in the complex treatment of the deep and/or ex-
tensive skin damage, facilitating the survival of pa-
tients and improving the quality of their life after the 
trauma. Further studies in this fi eld are rather urgent 
for the elaboration of new cellular technologies in 
biology and medicine.
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Різні типи біотехнологічних ранових покриттів,
створених з використанням живих клітин людини
О. Є. Папуга, Л. Л. Лукаш
В нинішній час залишається надзвичайно актуальною роз-
робка та впровадження в клінічну практику нових біотехно-
логічних ранових покриттів (еквівалентів шкіри), поклика-
них тимчасово або постійно замінювати пошкоджені або 
зруйновані ділянки шкіри людини. Серед штучних ранових 
покриттів особливе місце займають еквіваленти шкіри або її 
окремих шарів, що містять у своєму складі живі клітини різ-
них типів та походження. До складу біоконструкцій найчас-
тіше входять два основних типи клітин – фібробласти і кера-
тиноцити (спільно або окремо). Такі біоконструкцій слу-
жать, зазвичай, як тимчасові покриття, що забезпечують 
пошкоджену шкіру біологічно активними речовинами і сти-
мулюють регенерацію власних тканин пацієнта. У нашому 
огляді розглядаються як комерційно доступні раневі по-
криття, так і такі, які ще досліджуються в лабораторіях. 
Донині ще не створено ідеальних замінників шкіри, тому 
зусилля багатьох дослідників спрямовані на вирішення цьо-
го завдання.
Ключов і  слова: штучна шкіра, еквіваленти або замін-
ники шкіри, ранові дермальні покриття, тканинна інжене-
рія, клітина, опікова рана.
Различные типы биотехнологических
раневых покрытий, созданных с использованием
живых клеток человека
А. Е. Папуга, Л. Л. Лукаш
В настоящее время остаётся чрезвычайно актуальной разра-
ботка и внедрение в клиническую практику новых биотех-
нологических раневых покрытий (эквивалентов кожи), при-
званных временно или постоянно заменять повреждённые 
или разрушенные участки кожи человека. Среди искусст-
венных раневых покрытий особое место занимают эквива-
ленты кожи или её отдельных слоёв, имеющие в своём со-
ставе живые клетки различных типов и происхождения. В 
состав биоконструкций чаще всего входят два основных 
типа клеток – фибробласты и кератиноциты (совместно или 
отдельно). Такие биоконструкции служат, как правило, в ка-
честве временных покрытий, которые снабжают повреж-
денную кожу биологически активными веществами и сти-
мулируют регенерацию собственных тканей пациента. В 
нашем обзоре рассматриваются как коммерчески доступные 
раневые покрытия, так и те, которые ещё исследуются в ла-
бораториях. До настоящего времени ещё не созданы идеаль-
ные заменители кожи, поэтому усилия многих исследовате-
лей направлены на решение этой задачи.
Ключевые  слова: искусственная кожа, эквиваленты или 
заменители кожи, раневые дермальные покрытия, тканевая 
инженерия, клетка, ожоговая рана.
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